Skip to main content

Advertisement

SpringerLink
Log in

Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Celiac disease is the most common hereditary autoimmune disease in humans. The only treatment option for non-refractory celiac disease patients is adherence to a strict life-long gluten-free diet, which often fails to normalize small bowel histology. ALV003 is a mixture of two proteases that degrades gluten and is in clinical development as an oral therapy for patients with celiac disease.

Aims

The safety, tolerability, and activity of ALV003 were assessed in two phase 1 clinical trials.

Methods

In study 1 (N = 28) the study drug was administered in the fasted state; in study 2 (N = 53) the study drug was administered together with a gluten-containing meal. Both studies were single-dose, single-blind, placebo-controlled, cross-over trials. ALV003 was dosed at escalating dose levels by cohort (100, 300, 900, and 1,800 mg) and gastric samples were aspirated using a nasogastric tube. Adverse events, serum drug levels, and anti-drug antibody titers were measured. Gastric samples were assessed for ALV003 enzymatic activity over time (gastric pharmacokinetics) and gluten degradation (gastric pharmacodynamics).

Results

All doses were well tolerated, and no serious adverse events or allergic reactions were observed. Gastric aspirates collected 30 min following a meal showed that 100 and 300 mg ALV003 degraded 75 ± 10% (N = 8) and 88 ± 5% (N = 8), respectively, of one gram of wheat bread gluten.

Conclusions

ALV003 is an orally active protease that appears to be stable in the fed stomach and degrades dietary gluten in this compartment. Single doses of oral ALV003 were not associated with serious adverse reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297:2275–2279.

    Article  PubMed  CAS  Google Scholar 

  2. Marti T, Molberg O, Li Q, et al. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther. 2005;312:19–26.

    Article  PubMed  CAS  Google Scholar 

  3. Jabri B, Sollid LM. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol. 2006;3:516–525.

    Article  PubMed  CAS  Google Scholar 

  4. Green PH, Jabri B. Coeliac disease. Lancet. 2003;362:383–391.

    Article  PubMed  CAS  Google Scholar 

  5. Logan RF, Rifkind EA, Turner ID, et al. Mortality in celiac disease. Gastroenterology. 1989;97:265–271.

    PubMed  CAS  Google Scholar 

  6. Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet. 2001;358:356–361.

    Article  PubMed  CAS  Google Scholar 

  7. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286–292.

    Article  PubMed  Google Scholar 

  8. Mäki M, Mustalahti K, Kokkonen J, et al. Prevalence of celiac disease among children in Finland. N Engl J Med. 2003;348:2517–2524.

    Article  PubMed  Google Scholar 

  9. Leffler DA, Edwards George JB, Dennis M, et al. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. Aliment Pharmacol Ther. 2007;26:1227–1235.

    Article  PubMed  CAS  Google Scholar 

  10. Ciacci C, Cirillo M, Cavallaro R, et al. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion. 2002;66:178–185.

    Article  PubMed  CAS  Google Scholar 

  11. Lanzini A, Lanzarotto F, Villanacci V, et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther. 2009;29:1299–1308.

    Article  PubMed  CAS  Google Scholar 

  12. Bardella MT, Velio P, Cesana BM, et al. Coeliac disease: a histological follow-up study. Histopathology. 2007;50:465–471.

    Article  PubMed  CAS  Google Scholar 

  13. Rubio-Tapia A, Rahim MW, See JA, et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol. 2010;105:1412–1420.

    Article  PubMed  CAS  Google Scholar 

  14. Midhagen G, Hallert C. High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol. 2003;98:2023–2026.

    Article  PubMed  CAS  Google Scholar 

  15. Cranney A, Zarkadas M, Graham ID, et al. The Canadian celiac health survey. Dig Dis Sci. 2007;52:1087–1095.

    Article  PubMed  Google Scholar 

  16. Hopman E, Dekking L, Blokland ML, et al. Tef in the diet of celiac patients in The Netherlands. Scand J Gastroenterol. 2008;43:277–282.

    Article  PubMed  CAS  Google Scholar 

  17. Bethune MT, Strop P, Tang Y, et al. Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol. 2006;13:637–647.

    Article  PubMed  CAS  Google Scholar 

  18. Arentz-Hansen H, McAdam SN, Molberg O, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology. 2002;123:803–809.

    Article  PubMed  Google Scholar 

  19. Siegel M, Bethune MT, Gass J, et al. Rational design of combination enzyme therapy for celiac sprue. Chem Biol. 2006;13:649–658.

    Article  PubMed  CAS  Google Scholar 

  20. Stepniak D, Spaenij-Dekking L, Mitea C, et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol. 2006;291:G621–G629.

    Article  PubMed  CAS  Google Scholar 

  21. Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology. 2007;133:472–480.

    Article  PubMed  CAS  Google Scholar 

  22. Tye-Din J, Anderson R, French R, et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo: a randomised controlled trial. Clin Immunol. 2010;134:289–295.

    Article  PubMed  CAS  Google Scholar 

  23. US Food and Drug Administration. Substances generally regarded as safe. FDA regulation 21 CFR part 182, listing 182.3766. Available online at http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=786bafc6f6343634fbf79fcdca7061e1&rgn=div5&view=text&node=21:3.0.1.1.13&idno=21#21:3.0.1.1.13.4.1.16. Accessed 12 September 2011.

  24. European Parliament and Council. Directive no 95/2/EC: of 20 February 1995 on food additives other than colours and sweeteners. Annex III, Part B, pp. 27–30. Available online at http://www.eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:01995L0002-20060815:EN:NOT. Accessed 12 September 2011.

  25. US Food and Drug Administration. FDA inactive ingredients search for approved drug products. Search term: “Sodium Metabisulfite”. Available online at http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed 12 September 2011.

  26. Braden B, Adams S, Duan LP, et al. The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology. 1995;108:1048–1055.

    Article  PubMed  CAS  Google Scholar 

  27. Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology. 1993;104:1640–1647.

    PubMed  CAS  Google Scholar 

  28. Moron B, Bethune MT, Comino I, et al. Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic peptide. PLoS ONE. 2008;3:e2294.

    Article  PubMed  Google Scholar 

  29. Shan L, Marti T, Sollid LM, et al. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J. 2004;383:311–318.

    Article  PubMed  CAS  Google Scholar 

  30. Hue S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity. 2004;21:367–377.

    Article  PubMed  Google Scholar 

  31. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology/diagnosis/management. Vol 1, 8th ed. 2006:1190, 1195–1196.

  32. Maes BD, Ghoos YF, Geypens BJ, et al. Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. J Nucl Med. 1994;35:824–831.

    PubMed  CAS  Google Scholar 

  33. Mitea C, Havenaar R, Drijfhout JW, et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut. 2008;57:25–32.

    Article  PubMed  CAS  Google Scholar 

  34. Shan L, Qiao SW, Arentz-Hansen H, et al. Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. J Proteome Res. 2005;4:1732–1741.

    Article  PubMed  CAS  Google Scholar 

  35. García E, Llorente M, Hernando A, et al. Development of a general procedure for complete extraction of gliadins for heat processed and unheated foods. Eur J Gastroenterol Hepatol. 2005;17:529–539.

    Article  PubMed  Google Scholar 

  36. Simonian HP, Vo L, Doma S, et al. Regional postprandial differences in pH within the stomach and gastroesophageal junction. Dig Dis Sci. 2005;50:2276–2285.

    Article  PubMed  Google Scholar 

  37. Dressman JB, Berardi RR, Dermentzoglou LC, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7:756–761.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We acknowledge David A. Wagner from Metabolic Solutions, Inc. for data collection and analysis of 13C-acetate data. We acknowledge Biomedal S. L. for generously providing the A1 antibody. We also acknowledge Kirk Essenmacher for critical examination and helpful comments during manuscript preparation.

Author information

Authors and Affiliations

  1. Alvine Pharmaceuticals, 75 Shoreway Road, Suite B, San Carlos, CA, 94070, USA

    Matthew Siegel, Mitchell E. Garber, Andrew G. Spencer, Wendy Botwick, Pawan Kumar, Robert N. Williams, Kenji Kozuka, Revati Shreeniwas & Daniel C. Adelman

  2. Clinical Applications Laboratories, 3330 Third Ave #303, San Diego, CA, 92103, USA

    Vijaya Pratha

Authors
  1. Matthew Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell E. Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew G. Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wendy Botwick
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pawan Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert N. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenji Kozuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Revati Shreeniwas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vijaya Pratha
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel C. Adelman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Siegel.

Additional information

Matthew Siegel, Mitchell E. Garber, and Andrew G. Spencer contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siegel, M., Garber, M.E., Spencer, A.G. et al. Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials. Dig Dis Sci 57, 440–450 (2012). https://doi.org/10.1007/s10620-011-1906-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-011-1906-5

Keywords

Search

Navigation